Bepotastine: Preliminary Phase II/III data

Bepotastine met 1 of 2 primary endpoints in a U.S. Phase II/III trial. In the double-blind, placebo-controlled study, both 1% and 1.5% concentrations of the compound, dosed twice-daily significantly r...